ECHINOMYCIN (NSC-526417) IN SQUAMOUS-CELL CARCINOMA OF THE CERVIX - A PHASE-II TRIAL OF THE GYNECOLOGIC ONCOLOGY GROUP

被引：23
作者：
MUSS, HB
BLESSING, JA
MALFETANO, J
机构：
[1] ALBANY MED CTR,DEPT OBSTET & GYNECOL,ALBANY,NY
[2] WAKE FOREST UNIV,BOWMAN GRAY SCH MED,DEPT MED,WINSTON SALEM,NC 27103
[3] NEW YORK STATE DEPT HLTH,ROSWELL PK MEM INST,GYNECOL ONCOL GRP,DEPT STAT,BUFFALO,NY 14263
来源：
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS | 1990年 / 13卷 / 03期
关键词：
D O I：
10.1097/00000421-199006000-00002
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Twenty-eight evaluable patients with advanced or recurrent squamous-cell carcinoma of the cervix were treated with 1,500 μg/m2 of echinomycin every 4 weeks. All patients had prior chemotherapy. Two patients had partial responses (7% response, 95% confidence interval for response of 1 to 24%). The major toxicity was nausea and vomiting. Myelosuppression and other toxicity were modest. Echinomycin, at this dose and schedule, displays minimal activity in patients with squamous-cell carcinoma of the cervix who have had prior chemotherapy.
引用
收藏
页码：191 / 193
页数：3
相关论文
共 50 条
[31]   A phase II trial of pyrazoloacridine (PZA) in squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study [J].
Plaxe, SC ;
Blessing, JA ;
Olt, G ;
Husseinzadah, N ;
Lentz, SS ;
DeGeest, K ;
Valea, FA .
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2002, 50 (02) :151-154
[32]   PHASE-II TRIAL OF VP-16-213 IN THE TREATMENT OF ADVANCED SQUAMOUS-CELL CARCINOMA OF THE CERVIX AND ADENOCARCINOMA OF THE OVARY - GYNECOLOGIC ONCOLOGY GROUP-STUDY [J].
SLAYTON, RE ;
CREASMAN, WT ;
PETTY, W ;
BUNDY, B ;
BLESSING, JA .
CANCER TREATMENT REPORTS, 1979, 63 (11-1) :2089-2092
[33]   TENIPOSIDE (VM-26) IN PATIENTS WITH NON-SQUAMOUS-CELL CARCINOMA OF THE CERVIX - A PHASE-II TRIAL OF THE GYNECOLOGIC ONCOLOGY GROUP [J].
MUSS, HB ;
BUNDY, BN ;
GIVEN, FT ;
STEHMAN, FB .
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 1990, 13 (02) :117-118
[34]   A PHASE-II EVALUATION OF CISPLATIN AND 5-FLUOROURACIL IN PATIENTS WITH ADVANCED SQUAMOUS-CELL CARCINOMA OF THE CERVIX - A GYNECOLOGIC ONCOLOGY GROUP-STUDY [J].
BONOMI, P ;
BLESSING, J ;
BALL, H ;
HANJANI, P ;
DISAIA, PJ .
GYNECOLOGIC ONCOLOGY, 1989, 34 (03) :357-359
[35]   A phase II trial of gallium nitrate (NSC #15200) in nonsquamous cell carcinoma of the cervix - A gynecologic oncology group study [J].
Malfetano, JH ;
Blessing, JA ;
Homesley, HD .
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 1995, 18 (06) :495-497
[36]   Topotecan in squamous cell carcinoma of the cervix: A phase II study of the gynecologic oncology group [J].
Bookman, MA ;
Blessing, JA ;
Hanjani, P ;
Herzog, TJ ;
Andersen, WA .
GYNECOLOGIC ONCOLOGY, 2000, 77 (03) :446-449
[37]   PHASE-II TRIAL OF ETOPOSIDE IN THE MANAGEMENT OF ADVANCED OR RECURRENT SQUAMOUS-CELL CARCINOMA OF THE VULVA AND CARCINOMA OF THE VAGINA - A GYNECOLOGIC ONCOLOGY GROUP-STUDY [J].
SLAYTON, RE ;
BLESSING, JA ;
BEECHAM, J ;
DISAIA, PJ .
CANCER TREATMENT REPORTS, 1987, 71 (09) :869-870
[38]   Phase II clinical trial of docetaxel in refractory squamous cell carcinoma of the cervix - A gynecologic oncology group study [J].
Garcia, Agustin A. ;
Blessing, John A. ;
Vaccarello, Luis ;
Roman, Lynda D. .
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2007, 30 (04) :428-431
[39]   A phase II trial of pyrazoloacridine (PZA) in squamous carcinoma of the cervix - A Gynecologic Oncology Group study [J].
Plaxe, SC ;
Blessing, JA ;
Lucci, JA ;
Hurteau, JA .
INVESTIGATIONAL NEW DRUGS, 2001, 19 (01) :77-80
[40]   Cisplatin and pentoxifylline in advanced or recurrent squamous cell carcinoma of the cervix: A phase II trial of the gynecologic oncology group [J].
Mannel, RS ;
Blessing, JA ;
Boike, G .
GYNECOLOGIC ONCOLOGY, 2000, 79 (01) :64-66
12345